1 completed, 1 enrolling by invitation. 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Enrolling by invitation 1 |
| Phase 2 | 1 | Enrolling by invitation 1 |
| Phase 3 | 1 | Completed 1 |
Follow Low-Dose Naltrexone (LDN): new trials by email Literature Review of Low-Dose Naltrexone (LDN) trials Research Report on Low-Dose Naltrexone (LDN)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT) Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Sham Resonance Device (Inactive Control), Low-Dose Naltrexone (LDN) - Systemic Lupus Erythematosus, Rheumatoid Arthritis | Phase 1 / Phase 2 | Enrolling by invitation | Truway Health, Inc. | 120 | 2025-10-23 | 2026-05-22 |
| Combination Gerotherapeutic Interventions for Healthspan Improvement Rapamycin, Naltrexone, Metformin - Healthspan Improvement, Aging | Phase 3 | Completed | AgelessRx | 26 | 2025-07-23 | 2026-10-30 |
Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Lupus Erythematosus, Systemic (1) · Multiple Sclerosis (1)
AgelessRx (1) · Truway Health, Inc. (1)
United States (2)
Gavin Solomon, President & CEO (1) · Jenell Decker, MD (1) · Stefanie Morgan, PhD (1)